IPP Bureau
Syngene Q3 revenue up 13% to Rs. 585 Cr
By IPP Bureau - January 22, 2021
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
Shilpa Medicare CFO resigns
By IPP Bureau - January 20, 2021
The commercial production in the SML was started in November 1989.
Zydus eyes $6 bn market with strong COVID-19 portfolio
By IPP Bureau - January 18, 2021
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Dr. Reddy’s gets approval for Sputnik V Phase 3 trial
By IPP Bureau - January 16, 2021
The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.
Thermo Fisher completes acquisition of Henogen
By IPP Bureau - January 16, 2021
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Bayer gearing up for 2021-2030 decade
By IPP Bureau - January 16, 2021
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Vaishali Pharma bags order worth Rs. 32 Cr
By IPP Bureau - January 14, 2021
The company is expecting tremendous growth and a better quarterly performance
Commercial disinfectants equally as effective against new COVID strains: CBC
By IPP Bureau - January 13, 2021
Viruses evolve into new strains when there is a change to their genetic composition.
Dr. Reddy’s seeks approval to continue Phase 3 trial
By IPP Bureau - January 13, 2021
The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.
States need to capture vaccination data: R. S. Sharma
By IPP Bureau - January 11, 2021
Their feedback and the consequent changes in software/protocols based on those inputs were deliberated upon.
Biocon Biologics receives US $75 mn from ADQ; Valuation reaches US $4.17 Bn
By IPP Bureau - January 08, 2021
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
